RCM
CRL icon

Riverhead Capital Management’s Charles River Laboratories CRL Stock Holding History

Riverhead Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$440K Sell
3,324
-2,292
-41% -$307K 0.02% 772
2019
Q2 		$797K Buy
5,616
+1,492
+36% +$202K 0.03% 566
2019
Q1 		$599K Buy
4,124
+900
+28% +$118K 0.02% 627
2018
Q4 		$365K Sell
3,224
-750
-19% -$93.9K 0.02% 789
2018
Q3 		$535K Buy
3,974
+500
+14% +$61.7K 0.02% 724
2018
Q2 		$390K Sell
3,474
-1,650
-32% -$178K 0.02% 772
2018
Q1 		$547K Sell
5,124
-100
-2% -$10.8K 0.02% 619
2017
Q4 		$572K Buy
5,224
+3,000
+135% +$326K 0.02% 607
2017
Q3 		$240K Buy
2,224
+293
+15% +$30.1K 0.01% 904
2017
Q2 		$195K Buy
1,931
+247
+15% +$22.7K 0.01% 938
2017
Q1 		$151K Sell
1,684
-116
-6% -$9.85K 0.01% 844
2016
Q4 		$137K Buy
1,800
+900
+100% +$68.4K 0.01% 849
2016
Q3 		$75K Sell
900
-13,224
-94% -$1.11M ﹤0.01% 1019
2016
Q2 		$116K Buy
14,124
+6,424
+83% +$529K ﹤0.01% 1119
2016
Q1 		$585K Sell
7,700
-1,100
-13% -$81.4K 0.01% 807
2015
Q4 		$707K Buy
8,800
+6,600
+300% +$476K 0.01% 728
2015
Q3 		$140K Buy
+2,200
New +$158K ﹤0.01% 891

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Riverhead Capital Management's CRL Position: Q3 2019 in Review

Riverhead Capital Management reduced its Charles River Laboratories (CRL) stake by 41% in Q3 2019, selling an estimated $307K and leaving 3,324 shares worth $440K. The position accounts for 0.02% of the portfolio, ranked #772.

Riverhead Capital Management first reported a position in CRL in Q3 2015 and has held it in 17 quarters since. The position peaked at $797K in Q2 2019. 396 funds tracked by Wall St. Rank hold CRL as of Q3 2019.

  • Riverhead Capital Management held 3,324 shares of Charles River Laboratories worth $440K as of Q3 2019.
  • Riverhead Capital Management sold 2,292 Charles River Laboratories shares in Q3 2019, an estimated $307K.
  • Charles River Laboratories made up 0.02% of Riverhead Capital Management's portfolio in Q3 2019, its #772 holding.
  • Riverhead Capital Management first reported a position in Charles River Laboratories in Q3 2015 and has held it in 17 quarters since.
  • Riverhead Capital Management's Charles River Laboratories position peaked at $797K in Q2 2019.
  • 396 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.